Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Safety and Efficacy of AGN-199201 in Patients With Persistent Erythema Associated With Rosacea

Trial Profile

Safety and Efficacy of AGN-199201 in Patients With Persistent Erythema Associated With Rosacea

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 20 Feb 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Oxymetazoline (Primary)
  • Indications Erythema
  • Focus Therapeutic Use
  • Acronyms REVEAL 2
  • Sponsors Allergan
  • Most Recent Events

    • 30 Jan 2018 Primary endpoint (Percentage of Participants With at Least a 2-Grade Improvement (Decrease) From Baseline on Both Clinician Erythema Assessment (CEA) and Subject Self-Assessment for Rosacea Facial Redness (SSA) 5-point Scales) has been met as per the results published in the Journal of the American Academy of Dermatology
    • 30 Jan 2018 Results (n=885) of pooled analysis of REVEAL 1 and REVEAL 2 trials assessing safety and efficacy published in the Journal of the American Academy of Dermatology
    • 24 May 2017 Results from this and one other study (NCT02131636) assessing the Impact Assessment for Rosacea Facial Redness (IA-RFR) outcome, presented at the 22nd Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top